Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Aelis Farma S.A.S. is a biopharmaceutical company focused on the development of novel therapeutics for unmet medical needs. The company is particularly known for its pioneering research in developing specific CB1 receptor blockers that address pathologies related to neuropsychiatric and neurodevelopmental disorders. Aelis Farma's innovative approach targets disorders such as cannabis addiction, cognitive deficits related to Down syndrome, and other diseases associated with the endocannabinoid system. Operating within the dynamic field of biotechnology, Aelis Farma leverages advanced scientific research and clinical trials to advance its drug candidates through various stages of development. By addressing conditions with significant societal impacts, Aelis Farma plays a crucial role in the biopharmaceutical industry, striving to bring novel treatments to market that could significantly improve patient outcomes globally. Its work is vital in the medical community's ongoing efforts to tackle complex neuropsychological conditions.
€1.07
+€0.00 (+0.00%)
EOD Aug 17, 2026
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -€5M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€0.00
▼ -100.0% YoY
Net Income (TTM)
-€6M
▲ +13.7% YoY
Op. Margin
—
ROIC
-35.94%
▲ +0.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€5M
▲ +55.4% YoY
Op. Cash Flow (TTM)
-€5M
▲ +45.5% YoY
Net Debt
-€2M
Net Cash Position
Cash & Equiv.
€9M
Continue Research
Aelis Farma S.A.S. (AELIS.XPAR)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Aelis Farma S.A.S. scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Aelis Farma S.A.S. scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -35.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh AELIS.XPAR's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.